[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554327":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":54,"collaborators":29,"id":58,"slug":29,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":29,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":29,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":43,"whyStopped":29,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"group A","ACTIVE_COMPARATOR","this group will receive imipramine alone",[13],"Drug: Imipramine",{"label":15,"type":10,"description":16,"interventionNames":17},"group B","this group will receive sulbutiamine alone",[18],"Drug: Sulbutiamine",{"label":20,"type":10,"description":21,"interventionNames":22},"group C","this group will receive sulbutiamine plus imipramine",[18,13],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Sulbutiamine","sulbutiamine will be used by oral route 100 mg daily for 1 month and follow up will be done every 1 month till 3 months.\n\nit will be used alone in group B and combined with imipramine in group C",[15,20],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Imipramine","imipramine will be used by oral route 25 mg daily for 1 month and follow up will be done every 1 month till 3 months.\n\nit will be used alone in group A and combined with sulbutiamine in group C",[9,20],[35],{"name":36,"role":37,"phone":38,"phoneExt":29,"email":39},"loai mohammed abd alhamied, resident","CONTACT","01093873434","loaimohamed519@yahoo.com",[41],{"facility":42,"status":43,"city":44,"state":29,"zip":29,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Sohag Faculty of Medecine","RECRUITING","Sohag","Egypt",{"type":47,"coordinates":48},"Point",[49,50],31.69478,26.55695,{"lat":50,"lon":49},[53],{"name":36,"role":37,"phone":38,"phoneExt":29,"email":39},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Loai Mohammed Abd Al-Hamied","resident of urology , sohag university hospital","100554327",false,"NCT06497647","New Treatment for Nocturnal Enuresis in Children","Outcome of Treatment of Monosymptomatic Nocturnal Enuresis in Children Using Imipramine Alone Versus Sulbutiamine Alone Versus Imipramine Plus Sulbutiamine : Prospective Comparative Study","Inclusion Criteria:\n\n* Age : 6 - 18 years old.\n* All children diagnosed by Primary monosymptomatic nocturnal enuresis in this age group.\n\nExclusion Criteria:\n\n* Secondary nocturnal enuresis (child who has been continent for at least 6 months before the onset of bedwetting ).\n* congenital anomalies (Posterior urethral valve , ectopic ureter , ectopia vesica ,…)\n* history of previous lower urinary tract surgery (Multiple hypospadias surgeries ,…, )\n* neurogenic bladder (as underactive bladder ).and urge incontinence.\n* presence of post-void residual urine greater than 20% of functional bladder capacity.\n* history or evidence of disorders in other organs such as (cardiovascular system disease), liver , psychological problems , evident allergic reaction to both medication.",true,"ALL","6 Years","18 Years",{"count":69,"type":70},450,"ESTIMATED","INTERVENTIONAL",[73],"NA","The aim of the study is to evaluate the role of sulbutiamine in treatment of monosymptomatic nocturnal enuresis in children by using it alone or as a combination therapy with tricyclic antidepressants (imipramine+sulbutiamine).",[76],"Nocturnal Enuresis in Children",[78],"treatment of monosymptomatic nocturnal enuresis in children using sulbutiamine","2024-07-11",{"date":81,"type":82},"2024-07-12","ACTUAL",{"date":84,"type":82},"2024-03-01",{"date":86,"type":70},"2024-11",{"name":5,"class":6},1]